A Pentadecapeptide from Human Gastric Juice
BPC-157 — Body Protection Compound-157 — is a pentadecapeptide composed of 15 amino acids (molecular formula C62H98N16O22; CAS 137525-51-0) first isolated from human gastric juice. Its endogenous gastrointestinal origin is itself of research interest, as a peptide produced in the stomach and studied for cytoprotective and regenerative signaling in laboratory models.
The published research literature on BPC-157 spans several decades and comprises more than 700 published studies — an unusually large body for a single synthetic peptide. This depth makes BPC-157 one of the most characterized peptides in the regenerative research category in terms of preclinical literature.
Angiogenesis Research
A central thread in the BPC-157 literature is angiogenesis — the formation of new blood vessels from the pre-existing vasculature. Published laboratory research has examined BPC-157 in the context of:
- Vascular endothelial growth factor (VEGF) signaling pathways
- Fibroblast growth factor (FGF) modulation
- Endothelial nitric oxide (eNOS) signaling
- Collateral vessel formation in surgically prepared animal models
The proposed mechanism in these studies is that BPC-157 modulates the expression or activity of growth factors governing endothelial proliferation and migration. Researchers use BPC-157 as a tool to probe angiogenic signaling cascades without relying on a recombinant growth factor.
Growth Factor and Signaling Modulation
Beyond VEGF and FGF, the research literature describes BPC-157 interactions with additional signaling nodes. Published work has examined downstream pathway readouts relevant to cellular migration, extracellular matrix organization, and growth factor receptor activity in laboratory model systems. The peptide is studied as a signaling modulator rather than as a structural building block, which is a key conceptual distinction in interpreting the literature.
Researchers should note that much of the published BPC-157 data derives from rodent and in vitro models. The phrase "BPC-157 research indicates potential roles in..." reflects the laboratory framing; outcomes in animal models do not translate to or imply effects in humans.
Gastrointestinal Research Context
Given BPC-157's gastric origin, a substantial portion of the literature reports on gastrointestinal model research — intestinal mucosa integrity, endothelial barrier signaling, and gastric tissue model studies. This GI research thread is distinct from the angiogenesis/factor literature but shares conceptual overlap in signaling modulation.
BPC-157 in Blended Research Formulations
Because BPC-157 has such an extensive literature base, it is frequently combined with complementary peptides in blended research formulations to study concurrent signaling at multiple nodes. Notable research blends include:
- Wolverine Stack — BPC-157 combined with TB-500 (Thymosin Beta-4), studied for concurrent angiogenesis and actin/migration signaling
- Glow Blend — BPC-157 + TB-500 + GHK-Cu, adding the copper tripeptide for extracellular matrix and collagen synthesis research
- Klow Blend — BPC-157 + TB-500 + GHK-Cu + KPV, adding the melanocortin research peptide KPV (Lys-Pro-Val) to study anti-inflammatory signaling pathway interactions
Each blend encodes a different research hypothesis about which signaling axes, studied simultaneously, yield the most informative laboratory readout.
Research Framing
BPC-157 is supplied for laboratory and scientific research use only. It is not for human consumption, not a pharmaceutical, and not approved by the FDA for any medical use. Purchasers must be 21 years of age or older and are responsible for compliance with all applicable regulations.